BUZZ-AbbVie climbs on upbeat 2025 profit forecast

Shares of drugmaker AbbVie ABBV.N rise 3.5% to $181.84 premarket

ABBV expects 2025 adj. profit of $12.12 to $12.32 per share, compared to analysts' average estimate of $12.18 per share

Raises 2027 combined sales forecast for newer immunology drugs Skyrizi and Rinvoq to more than $31 bln from $27 bln earlier

Co reports Q4 adj. profit of $2.16 per share, beating analysts' average est. of $2.12 - LSEG data

Up to last close, stock up 6.5% in the last 12 months